The pharmaceutical company Bionure and the Hospital del Mar Research Institute, both members of CATALONIA.HEALTH, establish a strategic collaboration to transform the treatment landscape of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS) or Epilepsy, with RNA therapies.
The combination of Bionure’s innovative RNA technology with the clinical experience of the Hospital del Mar opens new possibilities for patients with neurodegenerative diseases that have a genetic component. Advanced RNA therapies not only seek to slow the progression of the disease but also offer the possibility of repairing neuronal damage.
Carmen Sanfrancisco, CEO of Bionure, says: "This collaboration marks a turning point in the treatment of neurodegenerative diseases. RNA therapies represent the future of personalized medicine in these complex conditions.”
Pablo Villoslada, director of the Neurosciences Research Program at the Hospital del Mar Research Institute, adds: "Our expertise in neuroscience, combined with Bionure's RNA technology, positions us at the forefront of translational research in central nervous system diseases."
Comments